

Corrigendum to: The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients

Aesthetic Surgery Journal
2021, Vol 41(12) 1494–1495
© 2021 The Aesthetic Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

www.aestheticsurgeryjournal.com

OXFORD
UNIVERSITY PRESS

Joely Kaufman-Janette, MD; Rui L. Avelar, MD; Brian S. Biesman, MD; Zoe Diana Draelos, MD; John E. Gross, MD, FACS; Derek H. Jones, MD; Mary P. Lupo, MD; Corey S. Maas, MD; Joel Schlessinger, MD; Ava Teresa Shamban, MD; Hema Sundaram, MD, FAAD; Susan H. Weinkle, MD; and Vernon L. Young, MD

In the article “The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients” by Kaufman-Janette et al in *Aesthet Surg J*, sjaa383, <https://doi.org/10.1093/asj/sjaa383>, errors were noted in co-author Joel Schlessinger’s name and disclosure statement. A corrigendum is being published to address the following changes that have subsequently been corrected:

In the author list and affiliations, co-author Joel Schlessinger’s full name should read: “Joel Schlessinger,” rather than how it previously appeared.

In the Disclosure section, the following text should read: “Dr Schlessinger is an investor and has served on the advisory board for Evolus; he is also a shareholder of AbbVie, and has served as a researcher for Merz, Galderma, Allergan/AbbVie and Croma Pharma,” rather than how it previously appeared.

DOI: 10.1093/asj/sjab229

Corrigendum to: The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients

Z. Paul Lorenc, MD, FACS; Jeffrey M. Adelglass, MD, FACS; Rui L. Avelar, MD; Leslie Baumann, MD; Kenneth R. Beer, MD; Joel L. Cohen, MD; Sue Ellen Cox, MD; Steven H. Dayan, MD; Jeffrey S. Dover, MD; Jeanine B. Downie, MD; Zoe Diana Draelos, MD; Mitchel P. Goldman, MD; John E. Gross, MD, FACS; John H. Joseph, MD; Joely Kaufman-Janette, MD; Ronald L. Moy, MD; Mark Nestor, MD; Joel Schlessinger, MD; Stacy R. Smith, MD; and Robert A. Weiss, MD

In the article “The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients” by Lorenc et al in *Aesthet Surg J.*, sjaa382, <https://doi.org/10.1093/asj/sjaa382>, in the originally published version of this manuscript, errors were noted in co-author Joel Schlessinger’s name, affiliation, and disclosure statement. This corrigendum corrects errors in the previously published version.

In the author list and affiliations, Joel Schlessinger’s full name should read: “Joel Schlessinger” and his affiliation

should read: “Dr Schlessinger is a dermatologist in private practice, Omaha, NE, USA.”

The Disclosure section should read: “Dr Schlessinger is a shareholder of Evolus, Inc., (Newport Beach, CA) and has served on the advisory board; he is also a shareholder of AbbVie Inc. (North Chicago, IL), and has served as a researcher for Merz (Frankfurt, Germany), Galderma (Lausanne, Switzerland), Allergan (Irvine, CA)/AbbVie (North Chicago, IL) and Croma Pharma (Leobendorf, Austria).” The author regrets these errors.

DOI: 10.1093/asj/sjab230

AESTHETIC SURGERY JOURNAL

OPEN FORUM

// *ASJ Open Forum's* commitment to excellence in aesthetic surgery is world class. The time, energy, and effort that *ASJ Open Forum* puts into every single peer-review manuscript process is a testament to their unwavering commitment to selecting the best of the best in all areas of aesthetic medicine and surgery. Our readers can rest assured that each month the content published is well-vetted and scrutinized to provide readers with world-class, evidence-based content to help them improve their own aesthetic practices. //

Chris Surek, DO

[@ASJrnl](https://twitter.com/ASJrnl) [f](https://www.facebook.com/AestheticSurgeryJournal) Aesthetic Surgery Journal [in](https://www.linkedin.com/company/aesthetic-surgery-journal) Aesthetic Surgery Journal [ig](https://www.instagram.com/aestheticsurgeryjournal_asj) aestheticsurgeryjournal_asj

academic.oup.com/asjopenforum



Follow Dr. Surek
[@dr.chrissurek](https://www.instagram.com/dr.chrissurek)

OXFORD
UNIVERSITY PRESS